BRCA2 and breast carcinoma: Nevertheless, the paucity of BRCA2-deficient breast cancers with PTEN mutation in this cohort (n = 1) precluded comparison of T cell-inflamed signature with BRCA2-deficient breast cancers without PTEN mutation.